凯辛圣佳威颗粒通过多组分和多目标机制改善认知功能,并减轻阿尔茨海默病中神经元损伤
Wei Liu1,2, Yanan Zhao3, Tingting Liu4
1Department of Neurology, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China.
Frontiers in pharmacology
|October 6, 2025
概括
凯辛圣贾威颗粒 (KSG) 通过调节神经递质,减少氧化应激和抑制炎症来改善阿尔茨海默病 (AD) 模型中的认知功能. 这种传统中医药通过多个目标和途径起作用,提供了一种新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 阿尔茨海默氏病 (AD) 构成一个重大挑战,传统中医 (TCM) 配方如Kaixin San Jiawei Granule (KSG) 显示出治疗潜力.
- 基于KSG在阿尔茨海默氏症治疗中的有效性的精确分子机制在很大程度上仍未被阐明,需要进行系统的调查.
研究的目的:
- 用综合网络药理学和实验验证方法系统地研究KSG在阿尔茨海默病 (AD) 中的分子机制.
- 确定关键活性化合物,分子标和参与KSG对AD治疗效果的信号通路.
主要方法:
- 使用斯科波胺建立一个体内AD小鼠模型和一个体内PC12细胞模型与Aβ暴露25-35.
- 评估认知功能,神经递质水平 (乙胆,乙胆酶),氧化应激标志物 (氨酸过氧化酶,活性氧物种),亡和炎症性细胞因子.
- 应用质谱学,网络药理学和分子对接来识别活性成分,标和途径,随后使用西式涂抹和qPCR进行实验验证.
主要成果:
- 在AD小鼠模型中,KSG显著改善了认知缺陷,恢复了乙胆水平,减少了氧化应激和乙胆酶活性.
- 在体外,KSG保护PC12细胞免受Aβ25-35诱导的细胞毒性,减少粉样β积累和下调的炎症标志物 (TNF-α,IL-1β).
- 网络药理学确定了基因斯坦,奎尔丁和阿皮基因是针对TP53,AKT1,PTGS2和CNR2的关键活性化合物,具有包括信号,PI3K-Akt和MAPK在内的丰富途径.
结论:
- 通过多组件,多目标协同机制,KSG对阿尔茨海默病 (AD) 产生治疗效果.
- 观察到的好处归因于胆固醇系统的调节,氧化应激和炎症的抑制,以及抑制神经元亡.
- 这些发现为开发基于中国传统医学的新型AD疗法提供了坚实的科学基础.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.凯信圣佳威颗粒剂 凯信圣佳威颗粒剂乙烯基胆是一种灭症 (apoptosis) 是一种死亡的过程.认知功能 认知功能炎症性细胞因子是炎症性细胞因子.网络药理学 网络药理学治疗疗法治疗疗法治疗疗法更多相关视频
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
2.0K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
